Qualigen Therapeutics

New York, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC (“Univest”), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of private placement of 5,100 Series A-2 Preferred Shares, with a stated value of US$1,000 per share, for its client Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (“Qualigen” or the “Company”), a life science company focused on developing platform treatments for adult and pediatric cancers, with the potential for orphan drug designations.» Mehr auf globenewswire.com

CARLSBAD, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it will implement a 1-for-50 reverse stock split of the issued shares of its common stock (the "Reverse Stock Split"), effective at 12:01 a.m. Eastern time on November 5, 2024. The Company's common stock is expected to begin trading on a split-adjusted basis when the market opens on Tuesday, November 5, 2024, and will continue to trade on The Nasdaq Capital Market under the symbol "QLGN." The new CUSIP number for the common stock will be 74754R 301.» Mehr auf globenewswire.com

CARLSBAD, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced on September 23, 2024, Mr. Michael Poirier, notified the board of directors of the Company (the Board") of his intention to resign as chief executive officer and Chairman of the Board of the Company, effective immediately. On the same date, Mr. Christopher Lotz, Chief Financial Office also tendered his resignation from the company, effective immediately. Both resignations were attributed to disagreements with the Company regarding its future direction and strategic initiatives.» Mehr auf globenewswire.com